NMDA-Receptor Antagonists and Opioid Receptor Interactions as Related to Analgesia and Tolerance Donald D Price, PhD, David J Mayer, PhD, Jianren Mao,

Slides:

Advertisements

Similar presentations

Molecular Biology of Opioid Analgesia

Advertisements

Opioid-Induced Bowel Dysfunction

Update on the Neurophysiology of Pain Transmission and Modulation

Pharmacoeconomics of Coxib Therapy

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO

The Public Health Strategy for Palliative Care

Effects of High Dose Opioids and Sedatives on Survival in Terminally Ill Cancer Patients Tatsuya Morita, MD, Junichi Tsunoda, MD, Satoshi Inoue, MD,

The Concept of Quality of Life of Dying Persons in the Context of Health Care Anita L Stewart, PhD, Joan Teno, MD, MS, Donald L Patrick, PhD, MSPH, Joanne.

Electrostatic Fasteners Hold the T Cell Receptor-CD3 Complex Together

Optimization of opioid therapy for preventing incident pain associated with bone metastases Sebastiano Mercadante, MD, Patrizia Villari, MD, Patrizia.

Anita L Comley, PhD, RN, AOCN, Elaine DeMeyer, RN, MSN, AOCN

James H. Flory, MD, MSCE, Alison C. Wiesenthal, MD, Howard T

Hospice and Palliative Care Development in India: A Multimethod Review of Services and Experiences Elizabeth McDermott, PhD, Lucy Selman, MPhil, Michael.

Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine Rainer Sabatowski, MD, Stefan.

Combination Analgesic Efficacy

Hydroxyurea and Acute Painful Crises in Sickle Cell Anemia: Effects on Hospital Length of Stay and Opioid Utilization During Hospitalization, Outpatient.

The Safety and Efficacy of a Single Dose (500 mg or 1 g) of Intravenous Magnesium Sulfate in Neuropathic Pain Poorly Responsive to Strong Opioid Analgesics.

NMDA-Receptor Antagonists in Neuropathic Pain

Double-Blind, Placebo-Controlled Trial of Lamotrigine in Combination with Other Medications for Neuropathic Pain Marianne Silver, MS, David Blum, MD,

David M. Dosa, MD, MPH, David D

Individual Difference Variables and the Effects of Progressive Muscle Relaxation and Analgesic Imagery Interventions on Cancer Pain Kristine L. Kwekkeboom,

How to Measure the International Development of Palliative Care

The symptoms of dying children

Morphine with Dextromethorphan

Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels in 2010, Its Relationship With Development Level, and Changes Compared.

Transdermal Fentanyl for Chronic Pain in AIDS

The Opioid Rotation Ratio From Transdermal Fentanyl to “Strong” Opioids in Patients With Cancer Pain Akhila Reddy, MD, Sriram Yennurajalingam, MD, MS,

David Clark, PhD, Michael Wright, PhD

Suntanu Dalal, MSc, Ronald Melzack, PhD

A Gray, H Kehlet, F Bonnet, N Rawal British Journal of Anaesthesia

Spinal Cord Stimulation for Critical Leg Ischemia: A Review of Effectiveness and Optimal Patient Selection Dirk Th. Ubbink, MD, PhD, Hester Vermeulen,

Characterization of the early pharmacodynamic profile of oral methadone for cancer- related breakthrough pain: a pilot study Kim Fisher, PhD, Carla Stiles,

A.G. Bradbury, M. Eddleston, R.E. Clutton

Suresh K Joishy, MD, FACP, Declan Walsh, MSc, FACP

Paul A. Sloan, MD, Dwight E. Moulin, MD, FRCP(C), Helen Hays, MD

Nicholas D. James, Jim W. Growcott European Urology Supplements

Opioid Therapies and Cytochrome P450 Interactions

Abuse Potential of Morphine/Dextromethorphan Combinations

This Month in AJKD American Journal of Kidney Diseases

Dose-response relationship between opioid use and adverse effects after ambulatory surgery Sean Z Zhao, PhD, MD, Frances Chung, MD, David B Hanna, MS,

Safety and Tolerability of Once-Daily OROS® Hydromorphone Extended-Release in Opioid-Tolerant Adults With Moderate-to-Severe Chronic Cancer and Noncancer.

Does regional anaesthesia improve outcome?

Methadone Analgesia in Cancer Pain Patients on Chronic Methadone Maintenance Therapy Paolo L Manfredi, MD, Gilbert R Gonzales, Andrea L Cheville, Craig.

Improving Access to Opioid Analgesics for Palliative Care in India

What Aspects of Quality of Life Are Important From Palliative Care Patients' Perspectives? A Systematic Review of Qualitative Research Nicola McCaffrey,

The COX-2 Specific Inhibitor, Valdecoxib, Is An Effective, Opioid-Sparing Analgesic in Patients Undergoing Total Knee Arthroplasty Lowell W Reynolds,

Reducing antibiotic use in influenza: challenges and rewards

Gertrud Andersen, MD, Lona Christrup, PhD, Per Sjøgren, MD

The Impact of Combined Use of Opioids, Antipsychotics, and Anxiolytics on Survival in the Hospice Setting Marin Golčić, MD, Renata Dobrila-Dintinjana,

Evaluating the Quality of Dying and Death

The Impact of Delirium on the Circadian Distribution of Breakthrough Analgesia in Advanced Cancer Patients Bruno Gagnon, MD, Peter G. Lawlor, MB, Isabelle.

Gabapentin and an Opioid Combination Versus Opioid Alone for the Management of Neuropathic Cancer Pain: A Randomized Open Trial Kader Keskinbora, MD,

Perceived Success in Addressing End-of-Life Care Needs of Low-Income Elders and Their Families: What Has Family Conflict Got to Do With It? Betty J.

Ketamine Use for Reduction of Opioid Tolerance in a 5-Year-Old Girl with End-Stage Abdominal Neuroblastoma Doralina L. Anghelescu, MD, Linda L. Oakes,

A Preliminary Study of the Utility of the Brief Hospice Inventory

Effects of capsazepine, a transient receptor potential vanilloid type 1 antagonist, on morphine-induced antinociception, tolerance, and dependence in.

A Titrated Morphine Analgesic Regimen Comparing Substance Users and Non-Users with AIDS-Related Pain Ronald Kaplan, MD, Joseph Slywka, PhD, Susan Slagle,

Physical Function in Patients with Cancer

Nathaniel P Katz, MD Journal of Pain and Symptom Management

Steady-State Pharmacokinetic Comparison of a New, Extended-Release, Once-Daily Morphine Formulation, Avinza™, and a Twice-Daily Controlled-Release Morphine.

Pain Management, Controlled Substances, and State Medical Board Policy

Molecular Biology of Opioid Analgesia

Multidimensional independent predictors of cancer-related fatigue

Optimizing Decision Making and Resource Allocation in Palliative Care

Nausea and Vomiting Remain a Significant Clinical Problem

Physical Activity Behaviors in Individuals with Multiple Sclerosis: Roles of Overall and Specific Symptoms, and Self-Efficacy Erin M. Snook, MS, Robert.

Use of oral and transdermal opioids among patients with metastatic cancer during the last year of life Ariel Berger, MPH, Ellen Dukes, PhD, RN, Meredith.

Patient-Controlled Analgesia for Children at Home

Gabapentin as an Adjuvant to Opioid Analgesia for Neuropathic Cancer Pain Augusto Caraceni, MD, Ernesto Zecca, MD, Cinzia Martini, MD, Franco De Conno,

Symptomatic Intravenous Antipyretic Therapy

Presentation transcript:

NMDA-Receptor Antagonists and Opioid Receptor Interactions as Related to Analgesia and Tolerance Donald D Price, PhD, David J Mayer, PhD, Jianren Mao, PhD, Frank S Caruso, PhD Journal of Pain and Symptom Management Volume 19, Issue 1, Pages 7-11 (January 2000) DOI: 10.1016/S0885-3924(99)00121-9

Fig. 1 Oral administration of MS 32 mg/kg with DM 8 to 64 mg/kg twice daily for 8 days. Animals receiving MS alone showed development of tolerance (rapid decline in maximal analgesic effect after day 3), while animals receiving MS:DM in ratios of 2:1, 1:1, and 1:2 remained responsive. In particular, MS:DM 1:1 appeared to be the optimal ratio for prevention of tolerance. Reproduced from Mao et al. (10) with permission Journal of Pain and Symptom Management 2000 19, 7-11DOI: (10.1016/S0885-3924(99)00121-9)

Fig. 2 Potentation of MS analgesia by DM following a single dose of the combination. Maximal analgesia with the combination was significantly greater than MS alone during the first 90 minutes after administration (P < 0.05). Reproduced from Mao et al. (10) with permission Journal of Pain and Symptom Management 2000 19, 7-11DOI: (10.1016/S0885-3924(99)00121-9)